B
녹십자홀딩스
005250KOSPI55.0 / 100
Reference Date: 2026-10-23
Financial Score22.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Samsung Biologics Holdings Co., Ltd. is a holding company established in 2001, managing 54 subsidiaries across five business segments, including pharmaceuticals, diagnostics, and healthcare services. While the holding company oversees strategic planning and portfolio management, subsidiaries handle operational activities. The company has expanded its domestic and international revenue and asset base.
Number of Employees
163people
Average Salary
78.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.25Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-2.31Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
39.54Industry Average 100.006.5Point
Half of industry avg (excellent)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲9.2% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲236.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -2.2% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 9,450Won52-week high 17,17052-week low 9,040
1-month return3.0Point
1m -0.63% (flat)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0